Skip to main content
S 183 115th Congress Senate Health Congressional oversight Drug safety, medical device, and laboratory regulation Prescription drugs Trade restrictions

Short on Competition Act

Introduced: January 20, 2017 Introduced by: Klobuchar, Amy Democratic · Minnesota See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 20, 2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Jan 20, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Short on Competition Act

This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to authorize importation of life-saving drugs for which there is, or is likely to be, a shortage. For a drug to be imported, the drug's manufacturer must intend to seek FDA approval of the drug as a generic drug. The FDA may deny importation of a drug for reasons related to safety or effectiveness.

Drugs in noncompetitive markets must be treated as being in a shortage for purposes of this bill and for purposes of expedited inspections and review. A drug is in a noncompetitive market if: (1) there are fewer than five holders of approved applications for commercially available brand name or generic versions of the drug, (2) the drug has been approved for at least 10 years, and (3) patents on the active ingredient of the drug have expired.
What's happening now January 20, 2017

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Democratic 1 Republican 2
D
Durbin, Richard J.
Illinois · Mar 5, 2018
 R
Grassley, Chuck
Iowa · Mar 5, 2018
 R
Lee, Mike
Utah · Jan 20, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). S. 183: Short on Competition Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-183/
MLA
"S. 183: Short on Competition Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-183/.
Bluebook (legal)
S. 183, 115th Cong. (2026), https://openamerica.io/bill/115-S-183/.
Markdown link
[S. 183: Short on Competition Act](https://openamerica.io/bill/115-S-183/)
Report a problem